COMMUNIQUÉS West-GlobeNewswire

GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor

20/09/2017 - 18:24

GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor Initial alert on potential medication error raised by Prescrire , an independent [...]

Summit Therapeutics plc : Holding(s) in Company

20/09/2017 - 17:15

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics [...]

Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

20/09/2017 - 15:03

Synthego strengthens position with appointment while accelerating worldwide commercial growth REDWOOD CITY, CA--(Marketwired - Sep 20, 2017) - Synthego , a leading provider of genome engineering solutions, announces the [...]

Optalysys, Ltd. Raises $4 Million Seed Round to Break Bottlenecks in Genomic Research and Big Data Analysis

20/09/2017 - 15:00

Light-Speed Optical Processing Startup to Democratize Access to High-Powered Computing and Drive Advances in Research and Development GLASSHOUGHTON, WEST YORKSHIRE, United Kingdom and RENO, Nev., Sept. 20, 2017 (GLOBE [...]

Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27

20/09/2017 - 14:00

ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

20/09/2017 - 14:00

AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its [...]

Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

20/09/2017 - 12:58

Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy - Investigational RNAi Therapeutic Patisiran Meets Primary [...]

Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine

20/09/2017 - 12:58

Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine - L'agent thérapeutique [...]

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer

20/09/2017 - 11:24

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer London (UK) - 20 September, 2017: Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal [...]

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD

20/09/2017 - 08:00

Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD Topline results revealed the study met its primary [...]

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

20/09/2017 - 07:15

Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM in the EU, Rydapt offers a new [...]

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

20/09/2017 - 07:00

Top-line data from the study expected in second half of 2018 - September 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]

Bone Therapeutics SA : announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

20/09/2017 - 07:00

Regulated information Bone Therapeutics announces all patients meet primary endpoint in ALLOB ® Phase I/IIA delayed-union study interim analysis DSMB recommends concluding the study early based on positive efficacy data [...]

Bone Therapeutics SA : Annonce que l'ensemble des patients ont satisfait au critère principal d'évaluation de l'analyse intérimaire de la Phase I/IIA avec ALLOB® dans les fractures avec retard de c...

20/09/2017 - 07:00

Information réglementée Bone Therapeutics annonce que l'ensemble des patients ont satisfait au critère principal d'évaluation de l'analyse intérimaire de la Phase I/IIA avec ALLOB ® dans les fractures avec retard de [...]

Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference

19/09/2017 - 22:05

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date [...]

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

19/09/2017 - 22:05

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company [...]

Participation de Nicox à la conférence annuelle Cantor Fitzgerald 2017 Global Healthcare

19/09/2017 - 17:45

Participation de Nicox à la conférence annuelle Cantor Fitzgerald 2017 Global Healthcare 19 septembre 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société [...]

Nicox to present at the Cantor Fitzgerald 2017 Global Healthcare Conference

19/09/2017 - 17:45

Nicox to present at the Cantor Fitzgerald 2017 Global Healthcare Conference September 19, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today [...]

EDAP Announces Opening of two New Ablatherm-HIFU Excellence Urology Centers in the U.S.

19/09/2017 - 15:15

University of Chicago Medicine - Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic Surgery Vituro Health LLC - Dr. S. Scionti, Medical Director and Director of The Scionti Prostate Center in Sarasota, FL [...]